TrialLeukemia2024

The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network.

Luca Fischer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.